Recurrent seizure at 60 months or greater · children with febrile seizures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: thromboses · minimal change disease in adults with nephrotic syndrome
It is very uncertain whether intravenous ± oral steroids changes adverse events: thromboses compared with oral steroids alone (very low certainty).
1 finding from 1 review
Gastrointestinal bleeding · minimal change disease in adults with nephrotic syndrome
It is very uncertain whether intravenous ± oral steroids changes adverse events: gastrointestinal bleeding compared with oral steroids alone (very low certainty).
1 finding from 1 review
Complete remission · minimal change disease in adults with nephrotic syndrome
It is very uncertain whether intravenous ± oral steroids changes complete remission Time frame: 2 to 28 months compared with oral steroids alone (very low certainty).
1 finding from 1 review
Complete or partial remission · minimal change disease in adults with nephrotic syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Relapse · minimal change disease in adults with nephrotic syndrome
It is very uncertain whether intravenous ± oral steroids changes relapse during compared with oral steroids alone (very low certainty).
1 finding from 1 review
Recurrent seizure at 6 months · children with febrile seizures
1 finding from 1 review
Recurrent seizure at 12 months · children with febrile seizures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrent seizure at 18 months · children with febrile seizures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrent seizure at 24 months · children with febrile seizures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrent seizure at 36 months · children with febrile seizures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrent seizure at 48 months · children with febrile seizures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrent seizure at 60 months or greater · children with febrile seizures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Successful treatment of exacerbation: number of participants cured. Outcome assessed on day 42 · bronchiectasis
It is very uncertain whether oral + inhaled dual therapy changes successful treatment of exacerbation: number of participants cured.… compared with oral monotherapy (very low certainty).
1 finding from 1 review
Successful treatment of exacerbation: number of participants with P aeruginosa eradication. Outcome assessed on day 21 · bronchiectasis
It is very uncertain whether oral + inhaled dual therapy changes successful treatment of exacerbation: number of participants with P… compared with oral monotherapy (very low certainty).
1 finding from 1 review
Serious adverse events. Outcome assessed on day 42 · bronchiectasis
It is very uncertain whether oral + inhaled dual therapy changes serious adverse events. Outcome assessed on day 42 compared with oral monotherapy (very low certainty).
1 finding from 1 review
Relapse · bronchiectasis
It is very uncertain whether oral + inhaled dual therapy changes treatment response: relapse (day 42). Outcome assessed on day 42 compared with oral monotherapy (very low certainty).
1 finding from 1 review
Microbiological response: eradicated. Outcome assessed on day 21 · bronchiectasis
It is very uncertain whether oral + inhaled dual therapy changes microbiological response: eradicated. Outcome assessed on day 21 compared with oral monotherapy (very low certainty).
1 finding from 1 review
Hospital admissions · bronchiectasis
1 finding from 1 review
Death · bronchiectasis
1 finding from 1 review